Zymeworks Azymetric™ Platform mabs attract GSK, Merck, Lilly & celgene
Reporter: Aviva Lev-Ari, PhD, RN
Azymetric™ Platform
The Azymetric™ platform was developed as the best-in-class solution for the development of IgG-like, novel bi-specific antibodies for the targeting of synergistic drug targets.
Azymetric™ bi-specific antibodies retain the desirable features of typical monoclonal antibodies, including:
Standard manufacturing processes with comparable production yieldsLong serum half-lifeAbility to mediate effector functionLow immunogenicity risk
Sourced through Scoop.it from: www.zymeworks.com
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
FrasonFrancis
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply